MedTrace Logo

RECAB-ASA; Treatment of Recurrent Abortion With Aspirin

NCT02823743 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2016-07-06

No results posted yet for this study

Summary

The aim of this study is to examine whether treatment with 75 mg aspirin daily compared with placebo could reduce the risk for a new miscarriage. The treatment starts when the pregnancy is detected on transvaginal ultrasound (around gestational week 6+) and continues to week 35/36. The study is a single center, randomized, placebo-controlled, double blind and stratified for age. 400 participants with the diagnosis idiopathic recurrent abortion are enrolled, 200 in each arm aspirin / placebo.

Conditions

  • Abortion, Habitual

Interventions

DRUG

Aspirin

Daily medication

DRUG

Placebo

Daily intake

Sponsors & Collaborators

  • Vastra Gotaland Region

    collaborator OTHER_GOV

  • Göteborg University

    lead OTHER

Principal Investigators

  • Annika Strandell, Ass.prof. · Göteborg University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Max Age
39 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2016-04-30
Completion
2016-06-30

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02823743 on ClinicalTrials.gov